Skip to main content
Equibles
RYTM logo

RYTM · Rhythm Pharmaceuticals, Inc. · Metrics

Track RYTM — free

Use RYTM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RYTM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$115.02 +5.16 (+4.70%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$7.97B
Shares
69.33M
Volume · Nov 13 1.16M Avg daily vol (3M) 997.95K

RYTM metrics

85 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$115.02
Market cap
$7.97B

Price action

23 metrics
Price change (1W)
+2.4%
Price change (30D)
+30.7%
Price change (3M)
-0.4%
Price change (6M)
+27.1%
Price change (YTD)
+7.5%
Price change (1Y)
+19.9%
Trailing year
Price change (5Y)
+773.3%
52-week high
$117.62
52-week low
$75.82
Change from 52-week high
-2.2%
Change from 52-week low
+51.7%
Annualized volatility
54.6%
Annualized volatility (3M)
67.4%
Implied volatility (30D)
65.6%
IV rank (1Y)
33.5
IV percentile (1Y)
48.6
Beta
1.2
RSI (14D)
66.3
Price vs SMA 50
+18.7%
Price vs SMA 200
+18.3%
Avg volume (3M)
997,954
Relative volume
1.2
Average dollar volume
$100.09M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
69.33M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
27.6×
reciprocal yield 3.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
28.4×
reciprocal yield 3.5%
P / book
90.7
reciprocal yield 1.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-2.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
30.2×
reciprocal yield 3.3%
EV / revenue historical average (5Y)
68.0×
reciprocal yield 1.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-03

Profitability

9 metrics
Gross margin
88.2%
Operating margin
-66.7%
Trailing 12 months
Net margin
-69.0%
Gross profit (TTM)
$247.69M
Operating profit (TTM)
−$187.25M
Net income (TTM)
−$193.81M
Trailing 12 months
Diluted EPS (TTM)
$-2.90
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$4.11
Gross profit per diluted share (TTM)
$3.63
Operating profit per diluted share (TTM)
$-2.75
EBITDA per diluted share (TTM)
$-3.17
Net income per diluted share (TTM)
$-2.85
Operating cash flow per diluted share (TTM)
$-1.21
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$2.64
Stock compensation per diluted share (TTM)
$1.37
Book value per share
$2.07

Growth

11 metrics
Revenue growth YoY
+79.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$280.75M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.2%
Year over year · more shares
Revenue CAGR (3Y)
+100.2%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-220.3%
Return on assets
-43.7%
Debt / equity
1.2
Current ratio
2.8
EBITDA (TTM)
−$153.13M
Free cash flow (TTM)
—
Quick ratio
2.6
Interest coverage
-10.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$218.28M
Latest balance sheet
Cash & equivalents
$39.98M
Total assets
$443.13M
Total debt
$102.67M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$81.79M
Capital expenditures (TTM)
$1.45M
R&D (TTM)
$179.66M
SG&A (TTM)
$255.27M
Stock compensation (TTM)
$93.45M
R&D / revenue
64.0%
Stock compensation / revenue
33.3%

Ownership (13F)

9 metrics
13F filers
308
13F filer change QoQ
+20
Institutional ownership
111.7%
Conviction holders (share of 13F filers)
3.2%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+3.4%
Holder tenure
15.3
Price vs estimated holder cost
+47.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
17.7%

Short interest

3 metrics
Short interest
16.8%
Latest settlement · 23.3 days to cover
Days to cover
23.3d
Short-squeeze score
89 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$11.75M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1649904 CUSIP 76243J105 13F (30d) 263 filings 226 filers Visit website Investor relations